Clinical Screening for COVID-19 in Asymptomatic Patients With Cancer

Manish A. Shah, MD; Sebastian Mayer, MD; Francie Emlen, MSN, MBA; Evan Sholle, MS; Paul Christos, PhD; Melissa Cushing, MD; Manuel Hidalgo, MD, PhD

Introduction

As the coronavirus disease 2019 (COVID-19) pandemic continues across the United States, a critical issue for practicing oncologists is how to continue cancer care while protecting patients.¹ To continue care for patients while also minimizing exposure to health care staff, the Weill Cornell Medicine Division of Hematology and Medical Oncology created separate units for patients with confirmed COVID-19, patients with symptomatic but unconfirmed COVID-19, and asymptomatic patients with no known high-risk COVID-19 exposures.² Patients were contacted prior to their appointment and triaged based on their COVID-19 risk status. To understand the success of our clinical screening and triaging procedures, we implemented a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing protocol in asymptomatic patients who required cancer care across the Division of Hematology and Medical Oncology.

Methods

This quality improvement study, approved by Weill Cornell Medicine, follows the Standards for Quality Improvement Reporting Excellence (SQUIRE) reporting guideline. Informed consent was waived because data were deidentified, per institutional policy.

Patients were considered asymptomatic if they had no recent fever (defined as body temperature ≥100.5 °F for ≥5 days); no COVID-19 symptoms, which included cough, headache, loss of taste, and shortness of breath³; or high risk exposure (eg, contact with an individual with confirmed COVID-19, nursing home stay, or hospitalization) within 14 days. Diagnosis of COVID-19 was confirmed using SARS-CoV-2 nasal swab polymerase chain reaction (PCR) testing (Cobas 6800; Roche Diagnostics) and SARS-CoV-2 IgM and IgG serological tests (Pylon 3D; ET HealthCare).⁴ Patients were retested every 1 to 2 weeks. Rates of positive SARS-CoV-2 PCR and COVID-19 serological tests and 95% CIs are reported, using the 2-sided Clopper-Pearson (exact) 95% CI. Statistical analyses were conducted using Stata statistical software version 13.1 (StataCorp).

Results

From April 30 through June 2, 2020, we performed 621 SARS-CoV-2 PCR tests on 537 asymptomatic patients (272 [50.7%] men) with hematologic or solid tumor malignant neoplasms (Table 1). Our patients were geographically representative of New York, New York, and surrounding areas, and more than 90% of patients were receiving active cytotoxic or targeted therapy. The rate of SARS-CoV-2 positivity was 0.64% (95% CI, 0.18%-1.64%). This includes 84 patients who had repeated SARS-CoV-2 tests, all of which were negative. Only 4 asymptomatic patients had test results positive for COVID-19, 2 each for hematologic and solid tumor neoplasms. We also performed serological tests from May 18 to June 2, 2020, on 238 asymptomatic patients. The rate of COVID-19 prior exposure in our asymptomatic cancer population was 4.23% (95% CI, 2.05%-7.65%) (Table 2). Notably, during this period, the SARS-CoV-2 PCR positivity rate in New York City in early May was 20%.⁵

Open Access. This is an open access article distributed under the terms of the CC-BY License.

JAMA Network Open. 2020;3(9):e2023121. doi:10.1001/jamanetworkopen.2020.23121
Discussion

The findings of this quality improvement study have several important implications. While it was clearly prudent to postpone elective procedures and delay care when possible, it is also clear that the risk of COVID-19 is likely to persist for some time. Cancer care will need to continue, given that further delays will lead to significantly worse outcomes for individual patients and other health care crises.

We observed that the rate of past infection in our clinically screened asymptomatic cancer population

| Table 1. Demographic Characteristics of Asymptomatic Testing Population |
|-----------------------------|-----------------------------|
| Characteristic             | No. (%) (N = 537)           |
| Men                        | 272 (50.7)                  |
| Race                       |                             |
| Black                      | 75 (14.0)                   |
| Asian                      | 47 (8.8)                    |
| White                      | 346 (64.4)                  |
| Othera                     | 24 (4.5)                    |
| American Indian            | 2 (0.4)                     |
| Unknown                    | 43 (8.0)                    |
| Borough                    |                             |
| Bronx                      | 31 (5.7)                    |
| Brooklyn                   | 113 (21.0)                  |
| Manhattan                  | 145 (27.0)                  |
| Queens                     | 88 (16.4)                   |
| Staten Island              | 17 (3.2)                    |
| Tri-state                  | 143 (26.6)                  |
| Hematologic characteristics|                             |
| No.                        | 299                         |
| Lymphoma                   | 57 (19)                     |
| Leukemia                   | 71 (23.7)                   |
| BMT                        | 72 (24.1)                   |
| Myeloma                    | 99 (33)                     |
| Solid tumor                |                             |
| No.                        | 238                         |
| Breast                     | 52 (21.8)                   |
| Lung                       | 31 (13.0)                   |
| Upper GI tract or hepatobiliary | 68 (28.6)      |
| Lower GI tract             | 65 (27.3)                   |
| Otherb                     | 22 (9.2)                    |

Abbreviations: GI, gastrointestinal; BMT, bone marrow transplant.

* Other combination or not described.

b Includes sarcoma, melanoma, head and neck, or neuroendocrine.

| Table 2. SARS-CoV-2 PCR and COVID-19 Serology Testing in Clinically Screened Asymptomatic Patient Populations |
|---------------------------------------------------------------------------------------------------|
| Tumor type                                           | SARS-CoV-2 PCR tests | COVID-19 serology tests |
|                                                     | No.                  | Positive result | Positive rate (95% CI), % | No.                  | Positive result* | Indeterminate result* | Positive rate (95% CI), % |
| Solid tumor                                          | 270                  | 2              | 0.74 (0.10-2.65)          | 131                  | 3              | 8                 | 2.29 (0.48-6.55)          |
| Hematologic malignant neoplasm                      | 351                  | 2              | 0.57 (0.07-2.04)          | 105                  | 7              | 3                 | 6.67 (2.72-13.25)          |
| Total                                                | 621                  | 4              | 0.64 (0.18-1.64)          | 236                  | 10             | 11                | 4.23 (2.05-7.65)          |

Abbreviations: COVID-19, coronavirus disease 2019; PCR, polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

* Positive was defined as value 1 or greater, and intermediate was defined as the mean index value plus 3 × SD divided by the instrument cutoff.
was exceedingly low, at approximately 4%, and the rate of SARS-CoV-2 PCR positivity was less than 1%. This is in contrast to the COVID-19 prevalence in New York City at that time, which was close to 20%. While we do not know the reason for this low prevalence rate, it is likely that these highly motivated patients abided to social distancing recommendations, masking, and hygiene. We found that patients whose test results were negative for COVID-19 could receive chemotherapy without increasing the risk of contracting the disease, further bolstering the argument that clinicians may resume anticancer therapy in asymptomatic patients. Our quality initiative study was limited by the relatively small sample size of our patients in racial/ethnic minority groups and relatively short patient follow-up. However, we found that with proper patient education and clinical screening for symptoms or viral exposure, we maintained the outpatient clinical arena largely free of SARS-CoV-2. These data provide some reassurance to health care workers and patients that oncological treatment may safely continue.
2. Shah MA, Emlen MF, Shore T, et al. Hematology and oncology clinical care during the coronavirus disease 2019 pandemic. CA Cancer J Clin. 2020. doi:10.3322/caac.21627

3. Mehta V, Goel S, Kabarriti R, et al. Case fatality rate of cancer patients with COVID-19 in a New York hospital system. Cancer Discov. 2020;10(7):935-941. doi:10.1158/2159-8290.CD-20-0516

4. Yang HS, Racine-Brzostek SE, Lee WT, et al. SARS-CoV-2 antibody characterization in emergency department, hospitalized and convalescent patients by two semi-quantitative immunoassays. Clin Chim Acta. 2020;509:117-125. doi:10.1016/j.cca.2020.06.004

5. Choi A, Velasquez J, Welch W. Coronavirus in New York City: tracking the spread of the pandemic. The City. Accessed July 26, 2020. https://projects.thecity.nyc/2020_03_covid-19-tracker/

6. Nagar H, Formenti SC. Cancer and COVID-19—potentially deleterious effects of delaying radiotherapy. Nat Rev Clin Oncol. 2020;17(6):332-334. doi:10.1038/s41571-020-0375-1